Author:
Ryff Jean-Charles,Pestka Sidney
Publisher
Springer International Publishing
Reference73 articles.
1. Aggarwal S, Ghilardi N, Xie M-H et al (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterised by the production of IL-17. J Biol Chem 278:1910–1914
2. Akdis M, Aab A, Altunbilakli C et al (2016) Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol 138(4):984–1010
3. Alfaro C, Sanmamed MF, Rodriguez ME et al (2017) Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 60:24–31
4. Algranati NE, Sy S, Modi M (1999) A branched methoxy 40-kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C. Hepatology 40:190A
5. Artillo S, Pastore G, Alberti A et al (1998) Double-blind, randomized controlled trial of interleukin-2 for the treatment of chronic hepatitis B. J Med Virol 54:167–172